GET DAILY SIGNALSCorbus Pharmaceuticals Holdings (CRBP): Examining the Path to a $35 Analyst Target
Key Takeaways
- The central target of $35 is the rounded arithmetic mean of nine verified analyst price targets collected from identifiable firms, with a current range of roughly $24 to $48.
- At a latest verified price near $4.00, reaching $35 would require an upside of roughly 775%, an extremely large move by any standard.
- The analyst consensus on CRBP is a "Strong Buy," yet targets have been repeatedly lowered as the share price has declined.
- The strongest supporting factors are the company's two pipeline assets, CRB-701 and CRB-913, and a heavily discounted micro-cap valuation.
- The biggest risks are a lack of meaningful revenue, ongoing cash burn, and the binary, data-dependent nature of clinical-stage drug development.
- Readers can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots to see AI-driven tools that monitor opportunities across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
The central target of $35 reflects the average of nine analyst price targets that could be verified with firm and date, not a single firm's call. Recent targets include Oppenheimer at $48, Guggenheim at $45, LifeSci Capital at $38, H.C. Wainwright at $35, RBC Capital and Jefferies at $33, B. Riley at $28, Wedbush at $27, and Mizuho at $24. The calculated mean is approximately $34.56, rounded to $35, with a low-to-high range of about $24 to $48.
The wide spread reflects genuine disagreement over clinical probability, not just valuation. The overall rating skews strongly bullish, with essentially all tracked firms at Buy or Outperform and no Hold or Sell ratings in recent months. However, the trend matters as much as the level: Wedbush trimmed its target from $30 to $27 in November 2026, Mizuho cut from $33 to $24 in late October 2026, and RBC Capital moved from $36 to $33. These cuts signal that analysts are repricing risk as the stock has fallen, even while maintaining constructive ratings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
CRBP last closed near $4.00, with a market capitalization of roughly $76 million and trailing twelve-month EPS of about negative $6.11. The 52-week range spans a low of $2.81 (set in November 2026) to a high of $12.88 (set in May 2026). Reaching $35 would require an upside of approximately 775% from current levels, which is a very large move for any equity and especially demanding for a company with minimal revenue.
Corbus is a clinical-stage developer with two principal programs: CRB-701, an antibody-drug conjugate targeting Nectin-4 in oncology, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. Because neither has yet generated commercial revenue, the path to $35 depends almost entirely on positive clinical data, successful regulatory milestones, and substantial financing to fund development. A return toward prior highs would require a sustained re-rating driven by evidence of efficacy and safety, not merely a technical rebound.
What Could Support a Move Toward the Target
The bullish case rests on the pipeline. H.C. Wainwright has pointed to CRB-701 data as strengthening the long-term outlook, and several firms cite upcoming catalysts around the oncology and obesity programs. A successful clinical readout could materially change the risk profile and justify a far higher valuation. The stock also trades below book value per share and at a micro-cap size where a single positive dataset can produce outsized percentage moves. Continued analyst coverage at Buy ratings, despite the decline, suggests conviction in the underlying science even as price targets are trimmed.
What Could Prevent the Target From Being Reached
The risks are substantial. Corbus generates negligible revenue and reported a quarterly GAAP net loss of roughly $23 million in the third quarter of 2025, with continued cash burn expected. Clinical-stage biotechs frequently require dilutive equity raises, which pressure shareholders. The company's own earnings have missed expectations, and any disappointing or ambiguous data from CRB-701 or CRB-913 could reset the valuation sharply lower, as the recent sell-off from above $12 to below $3 illustrates. Competition in both oncology ADCs and obesity treatments is intense, and the obesity program remains early-stage.
Technical Levels and Market Structure
The chart shows a pronounced downtrend, with CRBP falling roughly 70% from its 52-week high before stabilizing near the low. The $2.81 area now serves as a major support level, while $5 acts as a near-term psychological and resistance level. Above that, the $10 to $12.88 zone represents significant overhead supply from the 2026 decline. A durable base above $3 would be an early sign of stabilization, but the long-term structure remains bearish until the stock can reclaim materially higher levels.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of around 12 months, though the horizon is not explicitly stated by every firm and targets have been moving downward. Investors should monitor clinical data readouts for CRB-701 and CRB-913, quarterly earnings and cash-burn figures, any financing or dilution announcements, regulatory interactions, and further analyst target revisions. Because the stock is highly volatile (with a beta near 2.8), single-day and single-dataset moves can be extreme. From what I see, this volatility makes ongoing monitoring essential.
AI Daily Buy/Sell Signals
For traders tracking volatile names like CRBP, Tickeron's AI Daily Buy/Sell Signals offer a way to follow changing conditions more efficiently. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. In my view, it helps me discover opportunities, keep an eye on existing positions, and spot emerging trend changes without manually reviewing every chart. I find it a useful addition to my regular research process when evaluating names like this one.
Final Assessment
The $35 target is a calculated average of verified analyst price targets, and it sits roughly 775% above the current price of about $4.00. That gap reflects both the heavily discounted micro-cap valuation and the genuine uncertainty surrounding a clinical-stage pipeline with no meaningful revenue. The strongest supports are the oncology and obesity assets and the possibility of a positive data-driven re-rating; the principal obstacles are cash burn, dilution risk, and the binary nature of drug development. The $24-to-$48 analyst range shows that even bullish analysts disagree sharply on the stock's value. Whether CRBP can approach $35 will depend far more on clinical data and financing than on near-term price action.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRBP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CRBP turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRBP's RSI Oscillator exited the oversold zone, 31 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where CRBP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +28.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CRBP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.498). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of drug development services
Industry Biotechnology
Advertisement